Mainz Biomed FCF per Share

What does Mainz Biomed do? Mainz Biomed NV generates revenue through its genetic diagnostic testing services segment, offering products like ColoAlert, a stool-based DNA test for colorectal cancer screening, and PancAlert, a stool-based test for pancreatic cancer detection. The company also provides GenoStrip, a platform technology for molecular genetic pathogen detection in environments. Its primary customers include healthcare providers and diagnostic laboratories seeking advanced cancer screening solutions. Mainz Biomed competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc., and Agena Biosciences Inc. in the molecular genetics diagnostics market. The firm's product portfolio targets specific cancer types with non-invasive screening methods, focusing on colorectal and pancreatic cancers. ColoAlert and PancAlert are designed for early detection, while GenoStrip serves environmental pathogen monitoring. Mainz Biomed's revenue streams derive from the sale of these diagnostic tests and platform technology to healthcare institutions and laboratories. Mainz Biomed's business model centers on developing and commercializing molecular genetic diagnostic tools, with ColoAlert and PancAlert as key revenue drivers. The company's competitors in the diagnostics sector include Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc., and Agena Biosciences Inc., indicating a market focused on innovative cancer screening technologies. Mainz Biomed is one of the most popular companies on Eulerpool.